Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | SPEARHEAD-1: afamitresgene autoleucel in advanced synovial and myxoid liposarcoma

Robin Jones, MBBS, MRCP, MD, Royal Marsden NHS Foundation Trust, London, UK discusses the results of the SPEARHEAD-1 trial: a Phase II trial of the specific peptide enhanced affinity receptor (SPEAR) T-cell therapy afamitresgene autoleucel (formerly ADP-A2M4) in HLA-A*2 matched patients with MAGE-A4-positive advanced synovial and myxoid liposarcoma (NCT04044768). The objective response rate was 39%, the median duration of response was not reached, and cytokine release syndrome (CRS) was generally low grade. These results suggest that afamitresgene autoleucel may be an effective treatment option for patients with advanced synovial and myxoid liposarcoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.